Pharmacological characterization of MK-6096 - A dual orexin receptor antagonist for insomnia

Neuropharmacology

Volumn 62, Issue 2, 2012, Pages 978-987

  Winrow, Christopher J ^a   Gotter, Anthony L ^a   Cox, Christopher D ^a   Tannenbaum, Pamela L ^a   Garson, Susan L ^a   Doran, Scott M ^a   Breslin, Michael J ^a   Schreier, John D ^a   Fox, Steven V ^a   Harrell, Charles M ^a   Stevens, Joanne ^a   Reiss, Duane R ^a   Cui, Donghui ^a   Coleman, Paul J ^a   Renger, John J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hypocretin; Insomnia; MK 6096; Orexin; Pharmacology; Receptor occupancy

Indexed keywords

[5 [5 (FLUOROPYRIDIN 2 YLOXY)METHYL] 2 METHYLPIPERIDIN 1 YL] [5 METHYL 2 (PYRIMIDIN 2 YL)PHENYL]METHANONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALMOREXANT; CENTRAL NERVOUS SYSTEM AGENTS; DORA 22; MK 6096; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC RAT;

ANIMALS; DOGS; MICE; PIPERIDINES; PYRIMIDINES; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84855982509     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.10.003     Document Type: Article

References (55)

1. H. Ashton Guidelines for the rational use of benzodiazepines when and what to use Drugs 48 1994 25 40
2. R.M. Benca Diagnosis and treatment of chronic insomnia: a review Psychiatr. Serv. 56 2005 332 343
3. J.M. Bergman, A.J. Roecker, S.P. Mercer, R.A. Bednar, D.R. Reiss, R.W. Ransom, C. Meacham Harrell, D.J. Pettibone, W. Lemaire, K.L. Murphy, C. Li, T. Prueksaritanont, C.J. Winrow, J.J. Renger, K.S. Koblan, G.D. Hartman, and P.J. Coleman Proline bis-amides as potent dual orexin receptor antagonists Bioorg. Med. Chem. Lett. 18 2008 1425 1430
4. L.N. Boehmer, M.F. Wu, J. John, and J.M. Siegel Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity Exp. Neurol. 188 2004 292 299
5. P. Bonnavion, and L. de Lecea Hypocretins in the control of sleep and wakefulness Curr. Neurol. Neurosci. Rep. 10 2010 174 179
6. S.L. Borgland, S.A. Taha, F. Sarti, H.L. Fields, and A. Bonci Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine Neuron 49 2006 589 601
7. C. Brisbare-Roch, J. Dingemanse, R. Koberstein, P. Hoever, H. Aissaoui, S. Flores, C. Mueller, O. Nayler, J. van Gerven, S.L. de Haas, P. Hess, C. Qiu, S. Buchmann, M. Scherz, T. Weller, W. Fischli, M. Clozel, and F. Jenck Promotion of sleep by targeting the orexin system in rats, dogs and humans Nat. Med. 13 2007 150 155
8. R.M. Chemelli, J.T. Willie, C.M. Sinton, J.K. Elmquist, T. Scammell, C. Lee, J.A. Richardson, S.C. Williams, Y. Xiong, Y. Kisanuki, T.E. Fitch, M. Nakazato, R.E. Hammer, C.B. Saper, and M. Yanagisawa Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation Cell 98 1999 437 451
9. P.J. Coleman, J.D. Schreier, G.B. McGaughey, M.J. Bogusky, C.D. Cox, G.D. Hartman, R.G. Ball, C.M. Harrell, D.R. Reiss, T. Prueksaritanont, C.J. Winrow, and J.J. Renger Design and synthesis of conformationally constrained N, N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists Bioorg. Med. Chem. Lett. 2010
10. P.J. Coleman, J.D. Schreier, A.J. Roecker, S.P. Mercer, G.B. McGaughey, C.D. Cox, G.D. Hartman, C.M. Harrell, D.R. Reiss, S.M. Doran, S.L. Garson, W.B. Anderson, C. Tang, T. Prueksaritanont, C.J. Winrow, and J.J. Renger Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleeppromoting activity in the rat Bioorg. Med. Chem. Lett. 20 2010 4201 4205
11. E. Costa, and A. Guidotti Molecular mechanism in the receptor action of the benzodiazepines Annu. Rev. Pharmacol. Toxicol. 19 1979 531 545
12. C.D. Cox, M.J. Breslin, D.B. Whitman, J.D. Schreier, G.B. McGaughey, M.J. Bogusky, A.J. Roecker, S.P. Mercer, R.A. Bednar, W. Lemaire, J.G. Bruno, D.R. Reiss, C.M. Harrell, K.L. Murphy, S.L. Garson, S.M. Doran, T. Prueksaritanont, W.B. Anderson, C. Tang, S. Roller, T.D. Cabalu, D. Cui, G.D. Hartman, S.D. Young, K.S. Koblan, C.J. Winrow, J.J. Renger, and P.J. Coleman Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl- 1,4-diazepan-1-yl][5-methy l-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia J. Med. Chem. 53 2010 5320 5332
13. C.D. Cox, G.B. McGaughey, M.J. Bogusky, D.B. Whitman, R.G. Ball, C.J. Winrow, J.J. Renger, and P.J. Coleman Conformational analysis of N, N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding Bioorg. Med. Chem. Lett. 19 2009 2997 3001
14. L. de Lecea, T.S. Kilduff, C. Peyron, X. Gao, P.E. Foye, P.E. Danielson, C. Fukuhara, E.L. Battenberg, V.T. Gautvik, F.S. Bartlett 2nd, W.N. Frankel, A.N. van den Pol, F.E. Bloom, K.M. Gautvik, and J.G. Sutcliffe The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity Proc. Natl. Acad. Sci. U. S. A. 95 1998 322 327
15. S.A. Deadwyler, L. Porrino, J.M. Siegel, and R.E. Hampson Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates J. Neurosci. 27 2007 14239 14247
16. C.L. Drake, T. Roehrs, and T. Roth Insomnia causes, consequences, and therapeutics: an overview Depress Anxiety 18 2003 163 176
17. I.V. Estabrooke, M.T. McCarthy, E. Ko, T.C. Chou, R.M. Chemelli, M. Yanagisawa, C.B. Saper, and T.E. Scammell Fos expression in orexin neurons varies with behavioral state J. Neurosci. 21 2001 1656 1662
18. D.J. Foley, A.A. Monjan, S.L. Brown, E.M. Simonsick, R.B. Wallace, and D.G. Blazer Sleep complaints among elderly persons: an epidemiologic study of three communities Sleep 18 1995 425 432
19. N. Fujiki, L. Morris, E. Mignot, and S. Nishino Analysis of onset location, laterality and propagation of cataplexy in canine narcolepsy Psychiatry Clin. Neurosci. 56 2002 275 276
20. N. Fujiki, Y. Yoshida, B. Ripley, K. Honda, E. Mignot, and S. Nishino Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation Neuroreport 12 2001 993 997
21. N. Fujiki, Y. Yoshida, B. Ripley, E. Mignot, and S. Nishino Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog Sleep 26 2003 953 959
22. K.M. Gautvik, L. de Lecea, V.T. Gautvik, P.E. Danielson, P. Tranque, A. Dopazo, F.E. Bloom, and J.G. Sutcliffe Overview of the most prevalent hypothalamus specific mRNAs, as identified by directional tag PCR subtraction Proc. Natl. Acad. Sci. U. S. A. 93 1996 8733 8738
23. D. Georgescu, V. Zacharious, M. Barrot, M. Mieda, J.T. Willie, A.J. Eisch, M. Yanagisawa, E.J. Nestler, and R.J. DiLeone Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal J. Neurosci. 23 2003 3106 3111
24. S.P. Grady, S. Nishino, C.A. Czeisler, D. Hepner, and T.E. Scammell Diurnal variation in CSF orexin-A in healthy male subjects Sleep 29 2006 295 297
25. J. Hara, C.T. Beuckmann, T. Nambu, J.T. Willie, R.M. Chemelli, C.M. Sinton, F. Sugiyama, K. Yagami, K. Goto, M. Yanagisawa, and T. Sakurai Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity Neuron 30 2001 345 354
26. G.C. Harris, M. Wimmer, and G. Aston-Jones A role for lateral hypothalamic orexin neurons in reward seeking Nature 437 2005 556 559
27. W.J. Herring, K.S. Budd, J. Hutzelmann, E. Snyder, D. Snavely, K. Liu, C. Lines, D. Michelson, and T. Roth Efficacy and Tolerability of the Dual Orexin Receptor Antagonist MK-4305 in Patients with Primary Insomnia: Randomized, Controlled, Adaptive Crossover Polysomnography Study 2010 Association of Professional Sleep Societies Annual Meeting San Antonio, TX A0591
28. R. Hoque, and A.L. Chesson Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem J. Clin. Sleep Med. 5 2009 471 476
29. M. Hungs, J. Fan, L. Lin, X.Y. Lin, R.A. Maki, and E. Mignot Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines Genome Res. 11 2001 531 539
30. N.S. Kamel, and J.K. Gammack Insomnia in the elderly: cause, approach, and treatment Am. J. Med. 119 2006 463 469
31. J. Kaslin, J.M. Nystedt, M. Ostergard, N. Peitsaro, and P. Panula The orexin/hypocretin system in zebrafish is connected to the aminergic and cholinergic systems J. Neurosci. 24 2004 2678 2689
32. R.L. Kraus, Y. Li, Y. Gregan, A.L. Gotter, V.N. Uebele, S.V. Fox, S.M. Doran, J.C. Barrow, Z.Q. Yang, T.S. Reger, K.S. Koblan, and J.J. Renger In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice J. Pharmacol. Exp. Ther. 335 2010 409 417
33. P. Kunapuli, R. Ransom, K.L. Murphy, D. Pettibone, J. Kerby, S. Grimwood, P. Zuck, P. Hodder, R. Lacson, I. Hoffman, J. Inglese, and B. Strulovici Development of an intact cell reporter gene beta-lactamase assay for G protein-coupled receptors for highthroughput screening Anal. Biochem. 314 2003 16 29
34. M. Lancel Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists Sleep 22 1999 33 42
35. M.G. Lee, O.K. Hassani, and B.E. Jones Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle J. Neurosci. 25 2005 6716 6720
36. D. Leger Public health and insomnia: economic impact Sleep 23 Suppl. 3 2000 S69 S76
37. L. Lin, J. Faraco, R. Li, H. Kadotani, W. Rogers, X. Lin, X. Qiu, P.J. de Jong, S. Nishino, and E. Mignot The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene Cell 98 1999 365 376
38. K. Manabe, T. Matsui, M. Yamaya, T. Sato-Nakagawa, N. Okamura, H. Arai, and H. Sasaki Sleep patterns and mortality among elderly patients in a geriatric hospital Gerontology 46 2000 318 322
39. J.N. Marcus, C.J. Aschkenasi, C.E. Lee, R.M. Chemelli, C.B. Saper, M. Yanagisawa, and J.K. Elmquist Differential expression of oresin receptors 1 and 2 in the rat brain J. Comp. Neurol. 435 2001 6 25
40. T. Mochizuki, A. Crocker, S. McCormack, M. Yanagisawa, T. Sakurai, and T.E. Scammell Behavioral state instability in orexin knock-out mice J. Neurosci. 24 2004 6291 6300
41. S.D. Mosser, L. Stanley, S.L. Gaul, B. Bednar, K.S. Koblan, and R.A. Bednar Automation of in vitro dose-inhibition assays using the tecan genesis and an integrated software package to support the drug discovery process J. Assoc. Lab. Autom 8 2003 54 62
42. J.J. Renger, S.L. Dunn, S.L. Motzel, C. Johnson, and K.S. Koblan Sub-chronic administration of zolpidem affects modifications to rat sleep architecture Brain Res. 1010 2004 45 54
43. T. Roth New developments for treating sleep disorders J. Clin. Psychiatry 62 Suppl. 10 2001 3 4
44. T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richarson, G.P. Kozlowski, S. Wilson, J.R. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W.S. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, and M. Yanagisawa Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Cell 92 1998 1 page following 696
45. T. Sakurai, M. Mieda, and N. Tsujino The orexin system: roles in sleep/wake regulation Ann. N. Y. Acad. Sci. 1200 2010 149 161
46. T.E. Scammell, J.T. Willie, C. Guilleminault, and J.M. Siegel A consensus definition of cataplexy in mouse models of narcolepsy Sleep 32 2009 111 116
47. T.E. Scammell, and C.J. Winrow Orexin receptors: pharmacology and therapeutic opportunities Annu. Rev. Pharmacol. Toxicol. 51 2011 243 266
48. M.K. Stoller Economic effects of insomnia Clin. Ther. 16 1994 873 897 discussion 854
49. P. Trivedi, H. Yu, D.J. MacNeil, L.H. Van der Ploeg, and X.M. Guan Distribution of orexin receptor mRNA in the rat brain FEBS Lett. 438 1998 71 75
50. J.K. Walsh, and C.L. Engelhardt The direct economic costs of insomnia in the United States for 1995 Sleep 22 Suppl. 2 1999 S386 S393
51. D.B. Whitman, C.D. Cox, M.J. Breslin, K.M. Brashear, J.D. Schreier, M.J. Bogusky, R.A. Bednar, W. Lemaire, J.G. Bruno, G.D. Hartman, D.R. Reiss, C.M. Harrell, R.L. Kraus, Y. Li, S.L. Garson, S.M. Doran, T. Prueksaritanont, C. Li, C.J. Winrow, K.S. Koblan, J.J. Renger, and P.J. Coleman Discovery of a potent, CNS penetrant orexin receptor antagonist based on an n, n-disubstituted-1,4- diazepane scaffold that promotes sleep in rats ChemMedChem 4 2009 1069 1074
52. J.T. Willie, R.M. Chemelli, C.M. Sinston, H. Tokita, S.C. Williams, Y.Y. Kisanuki, J.N. Marcus, C. Lee, J.K. Elmquist, K.A. Kohlmeier, C.S. Leonard, J.A. Richardson, R.E. Hammer, and M. Yanagisawa Distinct narcolepsy dyndromes in orexin teceptor-2 and orexin null mice: molecular genetic fissection of non-REM and REM sleep regulatory processes Neuron 38 2003 715 730
53. C.J. Winrow, A.L. Gotter, C.D. Cox, S.M. Doran, P.L. Tannenbaum, M.J. Breslin, S.L. Garson, S.V. Fox, C.M. Harrell, J. Stevens, D.R. Reiss, D. Cui, P.J. Coleman, and J.J. Renger Promotion of sleep by Suvorexant-A novel dual orexin receptor antagonist J. Neurogenet. 25 2011 52 61
54. C.J. Winrow, K.Q. Tanis, D.R. Reiss, A.M. Rigby, J.M. Uslaner, V.N. Uebele, S.M. Doran, S.V. Fox, S.L. Garson, A.L. Gotter, D.M. Levine, A.J. Roecker, P.J. Coleman, K.S. Koblan, and J.J. Renger Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure Neuropharmacology 58 2010 185 194
55. G. Zammit Comparative tolerability of newer agents for insomnia Drug Saf. 32 2009 735 748